Alhambra Investment Management LLC Has $402,000 Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Alhambra Investment Management LLC lessened its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 5.9% in the fourth quarter, Holdings Channel.com reports. The fund owned 8,398 shares of the biopharmaceutical company’s stock after selling 531 shares during the quarter. Alhambra Investment Management LLC’s holdings in Halozyme Therapeutics were worth $402,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Skandinaviska Enskilda Banken AB publ acquired a new stake in shares of Halozyme Therapeutics during the second quarter worth $49,000. GAMMA Investing LLC grew its position in shares of Halozyme Therapeutics by 67.7% during the 3rd quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 350 shares during the period. Toth Financial Advisory Corp bought a new stake in shares of Halozyme Therapeutics in the 3rd quarter valued at about $57,000. FSC Wealth Advisors LLC acquired a new stake in shares of Halozyme Therapeutics in the 3rd quarter valued at approximately $65,000. Finally, Park Place Capital Corp boosted its stake in Halozyme Therapeutics by 828.1% during the 3rd quarter. Park Place Capital Corp now owns 1,355 shares of the biopharmaceutical company’s stock worth $78,000 after acquiring an additional 1,209 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

Insider Activity

In related news, Director Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00. Following the completion of the transaction, the director now owns 43,611 shares in the company, valued at approximately $2,180,986.11. This trade represents a 18.65 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 2.70% of the stock is owned by corporate insiders.

Halozyme Therapeutics Stock Performance

Shares of HALO opened at $54.80 on Friday. The stock has a market capitalization of $6.97 billion, a price-to-earnings ratio of 18.15, a PEG ratio of 0.40 and a beta of 1.24. Halozyme Therapeutics, Inc. has a 12 month low of $33.15 and a 12 month high of $65.53. The firm has a fifty day simple moving average of $49.62 and a 200 day simple moving average of $54.09. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32.

Analyst Upgrades and Downgrades

Several research firms have weighed in on HALO. Piper Sandler increased their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a report on Friday, January 10th. JMP Securities raised their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research note on Friday, November 1st. Cowen restated a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. HC Wainwright lifted their price objective on Halozyme Therapeutics from $68.00 to $70.00 and gave the company a “buy” rating in a report on Friday, January 10th. Finally, Wells Fargo & Company lowered their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $60.89.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.